Ultra-low dose naltrexone attenuates chronic morphine-induced gliosis in rats

Molecular Pain

Volumn 6, Issue , 2010, Pages

  Mattioli, Theresa Alexandra M ^a   Milne, Brian ^a   Cahill, Catherine M ^a,b  

^a QUEEN S UNIVERSITY   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; MORPHINE; NALTREXONE; SODIUM CHLORIDE; NARCOTIC ANTAGONIST;

ANIMAL EXPERIMENT; ANTIBODY LABELING; ARTICLE; ASTROCYTE; CELL ACTIVATION; CELL COUNT; CELL PROLIFERATION; CELL SIZE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG TOLERANCE; GLIA CELL; GLIOSIS; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MALE; MICROGLIA; NONHUMAN; PRIORITY JOURNAL; RAT; SPINAL CORD; THREE DIMENSIONAL IMAGING; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; DRUG TOLERANCE; GLIOSIS; IMAGING, THREE-DIMENSIONAL; IMMUNOHISTOCHEMISTRY; MALE; MORPHINE; NALTREXONE; NARCOTIC ANTAGONISTS; RATS; RATS, SPRAGUE-DAWLEY; SPINAL CORD;

EID: 77950844003     PISSN: 17448069     EISSN: None     Source Type: Journal    
DOI: 10.1186/1744-8069-6-22     Document Type: Article

References (50)

1. Cox BM. Molecular and cellular mechanisms in opioid tolerance. Towards a New Pharmacotherapy of Pain 1999, 137-156. John Wiley, Bausbaum AI, Besson JM.
2. Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, Glaser SE, Vallejo R. Opioid complications and side effects. Pain Physician 2008, 11(2-Suppl):S105-S120.
3. Matthes HW, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, Befort K, Dierich A, Le Meur M, Dollé P, Tzavara E, Hanoune J, Roques BP, Kieffer BL. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 1996, 383:819-823. 10.1038/383819a0, 8893006.
4. Koski G, Klee WA. Opiates inhibit adenylate cyclase by stimulating GTP hydrolysis. Proc Natl Acad Sci USA 1981, 78(7):4185-4189. 10.1073/pnas.78.7.4185, 319753, 6117072.
5. Eriksson PS, Hansson E, Ronnback L. Delta and kappa opiate receptors in primary astroglial cultures from rat cerebral cortex. Neurochem Res 1990, 15(11):1123-1126. 10.1007/BF01101714, 1982460.
6. Eriksson PS, Hansson E, Ronnback L. Mu and Delta opiate receptors in neuronal and astroglial primary cultures from various regions of the brain - coupling with adenylate cyclase, localization on the same neurones and association with dopamine (D1) receptors adenylate cyclase. Neuropharmacology 1991, 30(11):1233-1239. 10.1016/0028-3908(91)90170-G, 1663598.
7. Dobrenis K, Makman MH, Stefano GB. Occurrence of the opiate alkaloid-selective mu3 receptor in mammalian microglia, astrocytes and Kupffer cells. Brain Res 1995, 686(2):239-248. 10.1016/0006-8993(95)00452-V, 7583289.
8. Ruzicka BB, Fox CA, Thompson RC, Meng F, Watson SJ, Akil H. Primary astroglial cultures derived from several rat brain regions differentially express mu, delta and kappa opioid receptor mRNA. Brain Res Mol Brain Res 1995, 34(2):209-220. 10.1016/0169-328X(95)00165-O, 8750824.
9. Stiene-Martin A, Zhou R, Hauser KF. Regional, developmental, and cell cycle-dependent differences in mu, delta, and kappa-opioid receptor expression among cultured mouse astrocytes. Glia 1998, 22(3):249-259. 10.1002/(SICI)1098-1136(199803)22:3<249::AID-GLIA4>3.0.CO;2-0, 9482211.
10. Cheng PY, Liu-Chen LY, Pickel VM. Dual ultrastructural immunocytochemical labelling of μ and δ opioid receptors in the superficial layers of the rat cervical spinal cord. Brain Res 1997, 778(2):367-380. 10.1016/S0006-8993(97)00891-3, 9459554.
11. Powell KJ, Ma W, Sutak M, Doods H, Quirion R, Jhamandas K. Blockade and reversal of spinal morphine tolerance by peptide and non-peptide calcitonin gene-related peptide receptor antagonists. Br J Pharmacol 2000, 131:875-884. 10.1038/sj.bjp.0703655, 1572412, 11053206.
12. Powell KJ, Quirion R, Jhamandas K. Inhibition of neurokinin-1-substance P receptor and prostanoid activity prevents and reverses the development of morphine tolerance in vivo and morphine-induced increase in CGFP expression in cultured dorsal root ganglion neurons. Eur J Neurosci 2003, 18(6):1572-1583. 10.1046/j.1460-9568.2003.02887.x, 14511336.
13. Menard DP, van Rossum D, Kar S, Jolicoeur B, Jhamandas K, Quirion R. Tolerance to the antinociceptive properties of morphine in the rat spinal cord: alteration of calcitonin gene-related peptide-like immunostaining and receptor binding sites. J Pharmacol Exp Ther 1995, 273(2):887-894.
14. Price DD, Mayer DJ, Mao J, Caruso FS. NMDA-receptor antagonists and opioid receptor interactions as related to analgesia and tolerance. J Pain Symptom Manage 2000, 19(1):S7-S11. 10.1016/S0885-3924(99)00121-9, 10687332.
15. Mao J, Price DD, Mayer DJ. Thermal hyperalgesia in association with the development of morphine tolerance in rats: roles of excitatory amino acid receptors and protein kinase C. J Neurosci 1994, 14(4):2301-2312.
16. Trujillo KA, Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-901. Science 1991, 251:85-87. 10.1126/science.1824728, 1824728.
17. Raghavendra V, Tanga F, Rutkowski MD, DeLeo JA. Anti-hyperalgesic and morphine-sparing actions of propentofylline following peripheral nerve injury in rats: mechanistic implications of spinal glia and proinflammatory cytokines. Pain 2003, 104:655-664. 10.1016/S0304-3959(03)00138-6, 12927638.
18. Raghavendra V, Tanga FY, DeLeo JA. Attenuation of morphine tolerance, withdrawal-induced hyperalgesia, and associated spinal inflammatory immune responses by propentofylline in rats. Neuropsychopharmacology 2004, 29:327-334. 10.1038/sj.npp.1300315, 14532913.
19. Song P, Zhao Z. The involvement of glial cells in the development of morphine tolerance. Neurosci Res 2001, 39:281-286. 10.1016/S0168-0102(00)00226-1, 11248367.
20. Powell KJ, Abul-Husn NS, Jhamandas A, Olmstead MC, Beninger RJ, Jhamandas K. Paradoxical effects of the opioid antagonist naltrexone on morphine analgesia, tolerance, and reward in rats. J Pharmacol Exp Ther 2002, 300(2):588-596. 10.1124/jpet.300.2.588, 11805221.
21. Wang HY, Friedman E, Olmstead MC, Burns LH. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gβγ signaling. Neuroscience 2005, 135:247-261. 10.1016/j.neuroscience.2005.06.003, 16084657.
22. Shen KF, Crain SM. Ultra-low doses of naltrexone or etorphine increase morphine's antinociceptive potency and attenuate tolerance/dependence in mice. Brain Res 1997, 757:176-190. 10.1016/S0006-8993(97)00197-2, 9200746.
23. Chindalore VL, Craven RA, Peony Yu K, Butera PG, Burns LH, Friedmann N. Adding ultra-low dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of oxytrex. J Pain 2005, 6(6):392-399. 10.1016/j.jpain.2005.01.356, 15943961.
24. Webster LR, Butera PG, Moran LV, Wu N, Burns LH, Friedmann N. Oxytrex minimizes physical dependence while providing effective analgesia: a randomized controlled trial in low back pain. J Pain 2006, 7(12):937-946. 10.1016/j.jpain.2006.05.005, 17157780.
25. DeLeo JA, Colburn RW, Rickman AJ, Yeager MP. Intrathecal catheterization alone induces neuroimmune activation in the rat. Eur J Pain 1997, 1:115-122. 10.1016/S1090-3801(97)90069-0, 15102412.
26. Kurumaji A, Takashima M, Ohi K, Takahashi K. Circadian fluctuations in pain responsiveness and brain Met-enkephalin-like immunoreactivity in the rat. Pharmacol Biochem Behav 1988, 29(3):595-599. 10.1016/0091-3057(88)90025-1, 3362954.
27. O'Callaghan JP, Miller DB. Nervous system-specific proteins as biochemical indicators of neurotoxicity. Trends Pharmacol Sci 1983, 4:388-390.
28. Raghavendra V, Rutkowski MD, DeLeo JA. The role of spinal neuroimmune activation in morphine tolerance/hyperalgesia in neuropathic and sham-operated rats. J Neurosci 2002, 22(22):9980-9989.
29. Tawfik VL, LaCroix-Fralish ML, Nutile-McMenemy N, DeLeo JA. Transcriptional and translational regulation of glial activation by morphine in a rodent model of neuropathic pain. J Pharmacol Exp Ther 2005, 313(3):1239-1247. 10.1124/jpet.104.082420, 15743926.
30. Narita M, Suzuki M, Narita M, Yajima Y, Suzuki R, Shioda S, Suzuki T. Neuronal protein kinase Cγ-dependent proliferation and hypertrophy of spinal cord astrocytes following repeated in vivo administration of morphine. Eur J Neurosci 2004, 19:479-484. 10.1111/j.0953-816X.2003.03119.x, 14725643.
31. Cui Y, Chen Y, Zhi JL, Guo RX, Feng JQ, Chen PX. Activation of p38 mitogen-activated protein kinase in spinal microglia mediates morphine antinociceptive tolerance. Brain Res 2006, 1069(1):235-243. 10.1016/j.brainres.2005.11.066, 16403466.
32. Raghavendra V, Tanga F, DeLeo JA. Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J Pharmacol Exp Ther 2003, 306(2):624-630. 10.1124/jpet.103.052407, 12734393.
33. Sweitzer SM, Colburn RW, Rutkowski M, DeLeo JA. Acute peripheral inflammation induces moderate glial activation and spinal IL-1beta expression that correlates with pain behaviour in the rat. Brain Res 1999, 829(1-2):209-221. 10.1016/S0006-8993(99)01326-8, 10350552.
34. Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends NeuroscI 1996, 19(8):312-318. 10.1016/0166-2236(96)10049-7, 8843599.
35. Tsai RY, Tai YH, Tzeng JI, Lin SL, Shen CH, Yang CP, Hsin ST, Wang CB, Wong CS. Ultra-low dose naloxone restores the antinociceptive effect of morphine in pertussis toxin-treated rats and prevents glutamate transporter downregulation by suppressing the p38 mitogen-activated protein kinase signaling pathway. Neuroscience 2009, 159:1244-1256. 10.1016/j.neuroscience.2009.01.058, 19409222.
36. Crain SM, Shen KF. Opioids can evoke direct receptor-mediated excitatory effects on sensory neurons. Trends Pharmacol Sci 1990, 11:77-81. 10.1016/0165-6147(90)90322-Y, 2156364.
37. Wang HY, Frankfurt M, Burns LH. High-affinity naloxone binding to filamin A prevents mu opioid receptor-Gs coupling underlying opioid tolerance and dependence. PLoS ONE 2008, 3(2):e1554. 10.1371/journal.pone.0001554, 2212716, 18253501.
38. Hutchinson MR, Bland ST, Johnson KW, Rice KC, Maier SF, Watkins LR. Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward. ScientificWorldJournal 2007, 7:98-111. 10.1100/tsw.2007.57, 17982582.
39. La Vincente SF, White JM, Somogyi AA, Bochner F, Chapleo CB. Enhanced buprenorphine analgesia with the addition of ultra-low dose naloxone in healthy subjects. Clin Pharmacol Ther 2008, 83(1):144-152. 10.1038/sj.clpt.6100262, 17568402.
40. Imasogie NN, Singh S, Watson JT, Hurly D, Morley-Forster P. Ultra low dose naloxone and tramadol/acetaminophen in elderly patients undergoing joint replacement surgery: A pilot study. Pain Res Manage 2009, 14(2):103-108.
41. Garrison CJ, Dougherty PM, Kajander KC, Carlton SM. Staining of glial fibrillary acidic protein (GFAP) in lumbar spinal cord increases following a sciatic nerve constriction injury. Brain Res 1991, 565:1-7. 10.1016/0006-8993(91)91729-K, 1723019.
42. Sweitzer SM, Schubert P, DeLeo JA. Propentofylline, a glial modulating agent, exhibits antiallodynic properties in a rat model of neuropathic pan. J Pharmacol Exp Ther 2001, 297:1210-1217.
43. Jin SX, Zhuang ZY, Woolf CJ, Ji RR. P38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. J Neuroscience 2003, 23:4017-4022.
44. Tsuda M, Mizokoshi A, Shigemoto-Mogami Y, Koizumi S, Inoue K. Activation of p38 mitogen-activated protein kinase in spinal hyperactive microglia contributes to pain hypersensitivity following peripheral nerve injury. Glia 2004, 45:89-95. 10.1002/glia.10308, 14648549.
45. Arner S, Meyerson BA. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain 1988, 33:11-23. 10.1016/0304-3959(88)90198-4, 2454440.
46. Watkins LR, Hutchinson MR, Ledeboer A, Wieseler-Frank J, Milligan ED, Maier SF. Glial as the "bad guys": implications for improving clinical pain control and the clinical utility of opioids. Brain Behav Immun 2007, 21(2):131-146. 10.1016/j.bbi.2006.10.011, 1857294, 17175134.
47. Largent-Milnes TM, Guo W, Wang HY, Burns LH, Vanderah TW. Oxycodone Plus Ultra-Low-Dose Naltrexone Attenuates Neuropathic Pain and Associated μ-Opioid Receptor-Gs Coupling. J Pain 2008, 9(8):700-713. 10.1016/j.jpain.2008.03.005, 18468954.
48. Gouarderes C, Sutak M, Zajac JM, Jhamandas K. Role of adenosine in the spinal antinociceptive and morphine modulatory actions of neuropeptide FF analogs. Eur J Pharmacol 2000, 406:391-401. 10.1016/S0014-2999(00)00716-0, 11040346.
49. Suter MR, Berta T, Gao YJ, Decosterd I, Ji RR. Large A-fiber activity is required for microglial proliferation and p38 MAPK activation in the spinal cord: different effects of resiniferatoxin and bupivacaine on spinal microglial changes after spared nerve injury. Mol Pain 2009, 5:53. 10.1186/1744-8069-5-53, 2759920, 19772627.
50. Holdridge SV, Armstrong SA, Taylor AMW, Cahill CM. Behavioural and morphological evidence for the involvement of glial cell activation in delta opioid receptor function: implications for the development of opioid tolerance. Mol Pain 2007, 3:7. 10.1186/1744-8069-3-7, 1828713, 17352824.